Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Marinus Pharmaceuticals excels in Q4 with ZTALMY sales surge

Marinus Pharmaceuticals' Q4 2022 performance reflects strong demand for ZTALMY and progress in clinical pipeline development.
The company's strengths lie in successful product launches, intellectual property advancements, and a positive outlook for 2023.
Challenges include careful decision-making processes and efforts to expand patient reach and market awareness.
Opportunities for Marinus include global market expansion, increased disease diagnosis rates, and innovative drug development strategies.

Marinus Pharmaceuticals reports steady growth and strategic expansion opportunities

Marinus Pharmaceuticals demonstrated steady revenue growth and operational progress in advancing clinical programs and expanding market reach.
The company faces challenges in product development, trial management, and market dynamics but is well-positioned to capitalize on growth opportunities.
Strategic initiatives in IP portfolio expansion, market expansion in new regions, and a focus on innovation and patient safety underpin the company's growth trajectory.
CEO's strategic vision, emphasis on market exclusivity, and confidence in franchise longevity signal a strong foundation for future success and market leadership.

Marinus Pharmaceuticals reports robust earnings, faces trial enrollment challenges

Marinus Pharmaceuticals shows strong financial performance and operational resilience in Q2 2023.
The company faces challenges in trial enrollment delays but maintains a focus on innovation and market expansion.
Opportunities lie in product diversification, market growth, and demonstrating the value of their drug portfolio.

Marinus Pharmaceuticals surpasses revenue targets, eyes global expansion opportunities

Marinus Pharmaceuticals demonstrated strong financial performance in Q3 2023, with revenue exceeding expectations and a healthy cash position.
The company's strategic focus on expanding ZTALMY access globally and prioritizing high-value patient populations showcases a promising growth trajectory.
Challenges such as high screening attrition rates and gross to net deductions are being addressed, while opportunities in patient population expansion and program pricing present avenues for future success.
Overall, Marinus Pharmaceuticals is well-positioned for continued growth and innovation in the pharmaceutical market, supported by ongoing clinical trials and strategic initiatives.

Marinus Pharmaceuticals beats revenue targets, eyes blockbuster franchise growth

Marinus Pharmaceuticals showed strong performance in Q4 2023 with revenue exceeding guidance
Financially, the company is well-positioned with a healthy cash balance and controlled operating expenses
Challenges include increased R&D expenses and cash burn, but opportunities lie in revenue growth and market readiness
Excitement surrounds the progress of IV ganaxolone trials and potential blockbuster franchise plans

Marinus Pharmaceuticals excels with ZTALMY profitability and global expansion

Marinus Pharmaceuticals has shown strong performance with ZTALMY and the TSC trial, supported by strategic financial actions and operational advancements.
While facing challenges in maintaining growth momentum and patient acquisition, the company is well-positioned for global expansion and profitability post-TSC launch.
Opportunities lie in expanding market access, enhancing manufacturing capabilities, and preparing for a successful launch in key regions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022. “2022 was a year of significant growth and execution for Marinus, underscored by the successful U.S. launch of ZTALMY,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on March 7, 2023. Participants may access the conference call via webcast on the Investor page of Marinus' website at ir.

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee.

Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN. Marinus will also host a scientific exhibit and investor breakfast event with members of its leadership team to highlight ganaxolone's potential across a range of seizure disorders and discuss its commercial progress and strategy.

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a China-based biotechnology company focused on the development of innovative treatments for central nervous system (CNS) disorders. Under the terms of the agreement, Tenacia will receive exclusive rights to develop and commercialize certain formulations of ganaxolone in Mainland China, Hong Kong, Macau and Taiwan, including the current oral and intravenous (IV) dose formulations and a right of first negotiation for a future next generation formulation or prodrug.

Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

RADNOR, Pa.--( BUSINESS WIRE )--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board. Dr. Braunstein succeeds Nicole Vitullo, who has retired from the Board of Directors following a 17-year tenure, including the past three years as Chairwoman.

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

Ardagh Metal Packaging SA

Bed Bath & Beyond

GrowGeneration Corp

Kinross Gold

Nu Holdings

Olaplex Holdings

Opendoor

Redfin

SomaLogic

More penny stocks with unusual options activity right now. The post 10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

10 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

More penny stocks with unusual options activity right now. The post 7 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

7 Hot Penny Stocks With Unusual Options Activity, Time To Buy?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Sasha Damouni Ellis – Vice President-Corporate Affairs and Investor Relations Scott Braunstein – Chief Executive Officer Christy Shafer – Chief Commercial Officer Joe Hulihan – Chief Medical Officer Steve Pfanstiel – Chief Financial Officer Conference Call Participants Joseph Thome – Cowen and Company Andrew Tsai – Jefferies Douglas Tsao – H.C. Wainwright Jay Olson – Oppenheimer Operator Ladies and gentlemen, greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Call.

Marinus Pharmaceuticals, Inc. (MRNS) Q3 2022 Earnings Call Transcript

Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals Announces Proposed Public Offering

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners

Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022

Mizuho Financial Group

Panasonic Holdings Corp

Solid Biosciences

Trupanion

It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out of their positions, the dynamic presents discounted opportunities for battle-hardened contrarians.

7 Sizzling Stocks That Are Oblivious to the Manic Market

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

Today, we put Marinus Pharmaceuticals back in the spotlight as the stock has held up well even as the market has sold off. The company also has seen some positive news flow of late including the sale of a priority review voucher and some additional cash flow from BARDA.

Marinus Pharmaceuticals: Positive News Flow Of Note

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Sasha Ellis - VP, Corporate Affairs & IR Scott Braunstein - CEO, President & Director Christy Shafer - Chief Commercial Officer Joseph Hulihan - Chief Medical Officer Steven Pfanstiel - CFO & Treasurer Conference Call Participants Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald & Co. Douglas Tsao - H.C. Wainwright & Co. Jay Olson - Oppenheimer Michael Higgins - Ladenburg Thalmann & Co. Brian Skorney - Robert W.

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q2 2022 Results - Earnings Call Transcript

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Marinus Pharmaceuticals Stock (MRNS)